OBJECTIVE: Evaluate the effects of osilodrostat short- and long-term treatment on health-related quality of life (HRQoL) in Cushing's disease. DESIGN: LINC 3 and LINC 4 studies (pooled analysis). PATIENTS: 185 patients (mean baseline total scores: Cushing's Quality of Life CushingQoL, 44.0; Beck Depression Inventory II BDI-II, 15.6; EuroQol Five Dimensions Five Levels EQ--5D-5L, 0.7). MEASUREMENTS: Changes from baseline in CushingQoL, BDI--II and EQ-5D-5L scores. CushingQoL and EuroQol Five Dimensions Three Levels (EQ-5D-3L) scores were assessed in analyses of hypocortisolism-related adverse events (HAEs). RESULTS: Mean CushingQoL score improved (all p 2-5 × ULN) and severe (mUFC > 5 × ULN) hypercortisolism. BDI-II and EQ-5D-5L total scores improved in patients with moderate and severe hypercortisolism. Grade 3 HAEs temporarily reduced CushingQoL and EQ-5D-3L scores during event weeks. In the multivariable models, longer treatment duration was associated with CushingQoL improvements; higher mUFC, higher body mass index, and occurrence of HAEs were associated with lower CushingQoL scores. CONCLUSIONS: Osilodrostat improved HRQoL, with clinically meaningful, consistent improvements across HRQoL assessments.
Newell‐Price et al. (Mon,) studied this question.